Why Are DHA+ARA Known As The Golden Duo? What Are The Limitations Of DHA-only Supplementation?

In the fields of infant nutrition, maternal-infant food and dietary supplements, DHA, widely known as "brain gold", has become a core nutritional indicator for parents when selecting products and for purchasers when screening supplies. However, many people wonder: why do high-end infant formula foods and infant nutritional supplements all feature the DHA+ARA combination instead of DHA alone? What exactly makes the industry-recognized "golden duo of DHA+ARA" so valuable? What tangible drawbacks come with DHA-only supplementation? This article uses plain, accessible language, taking into account both parenting needs of ordinary consumers and product-selection logic of purchasers, to comprehensively unpack their synergistic benefits and the limitations of single-nutrient supplementation.

A core conclusion should be established upfront: DHA and ARA are not simply additive nutrients; rather, they are indispensable, mutually complementary functional partners whose synergistic effects cannot be replicated by either nutrient alone. This is the core reason behind their reputation as the "golden duo". Breast milk, the gold standard for infant nutrition, naturally contains both DHA and ARA at a scientifically validated ratio of 1:1 to 1:2, with the optimal golden ratio around 1:1.7. This optimised nutritional pairing shaped by millions of years of natural evolution serves as the reference benchmark for all infant formula foods and nutritional supplements.

In terms of functional division, DHA and ARA play distinct yet complementary roles, jointly supporting infant ocular-brain development, physical growth and immune regulation. Most people only know that DHA benefits brain and eye health, yet few understand its primary role: forming the fundamental framework of the nervous and visual systems. As a key component of the cerebral cortex and retina, DHA enhances cell-membrane fluidity, accelerates nerve-signal transmission, and directly facilitates infants' visual development, cognitive improvement and concentration development. It acts as the "cornerstone" of nervous-system maturation.

ARA, by contrast, precisely offsets DHA's functional shortcomings and serves as the "critical driving force" for translating nutritional benefits into tangible physiological outcomes. ARA, or arachidonic acid, is abundant in the human brain, liver and immune cells. Its core functions include perfecting cellular structures, regulating physiological signalling, supporting growth and development, and bolstering immune responses. If DHA builds the "architectural framework" of the brain and visual system, ARA functions as the construction material and power system that refines details, reinforces structures and activates physiological functions. Clinical research confirms that ARA accounts for 40%-50% of fatty acids in the cerebral cortex, far exceeding DHA's 20% share - evidence of ARA's irreplaceable core status in brain development.

Combined, the two nutrients deliver synergistic benefits greater than the sum of their individual effects (1+1>2). DHA enables efficient nerve-signal transmission for quicker responses and sharper vision in infants; ARA consolidates nerve-cell structures, promotes brain-cell proliferation and differentiation, and supports bone growth and immune-system maturation. This dual synergy fosters comprehensive intellectual and visual development while avoiding developmental deficits stemming from single-nutrient deficiency - this embodies the core value of the "golden duo".

Compared with well-proportioned combined supplementation, DHA-only supplementation carries notable limitations and may even produce counterproductive effects, which explains why single-ingredient DHA supplementation is not recommended across the industry.

First, exclusive DHA supplementation inhibits endogenous ARA synthesis and triggers nutritional imbalance. DHA and ARA share the same metabolic enzymes in the human body. Infants possess only 10%-30% of adults' metabolic-enzyme activity, resulting in inherently limited metabolic capacity. Large-dose DHA-only supplementation seizes metabolic resources, directly suppressing ARA synthesis and absorption and leading to insufficient bodily ARA levels. This seesaw-style nutritional imbalance counteracts DHA supplementation benefits and substantially slows ocular-brain development.

Second, DHA-only intake fails to support comprehensive growth and development and may lead to developmental delays. DHA focuses exclusively on nervous-system and visual development and does not participate in core physiological processes such as physical growth and immune modulation. Without ARA's supporting role, infants are prone to suboptimal growth rates, weak physical development, compromised immunity, and increased susceptibility to colds and allergies. Multiple paediatric controlled clinical trials show that infants receiving DHA-only supplementation score up to 7 points lower on mental-development indices and physical-growth indicators at 18 months of age, compared with infants receiving balanced DHA+ARA supplementation.

Third, DHA-only supplementation results in incomplete neural-function development and drastically diminished nutritional returns. Full-fledged brain development requires not only DHA to build nerve-transmission pathways but also ARA to refine neural-synaptic connections and modulate cellular signalling. Without ARA support, the neural framework built by DHA cannot achieve functional implementation, creating a scenario of "structure without function". This manifests as slower cognitive responses and weaker learning and adaptability in infants, failing to deliver expected brain-boosting outcomes. Furthermore, ARA deficiency compromises retinal-cell stability, preventing optimal visual development.

Fourth, from a long-term nutritional perspective, DHA-only supplementation runs counter to human innate nutritional patterns. DHA never occurs in isolation in breast milk; it always co-exists with ARA in balanced proportions - a natural nutritional pattern adapted to infant physiology. Artificially breaking this pattern through long-term DHA-monotherapy may disrupt bodily fatty-acid metabolism, impairing infant-stage development and posing potential risks to long-term immune and metabolic health.

For consumers, understanding this principle helps avoid the parenting pitfall of fixating solely on DHA content. Many parents blindly pursue higher DHA concentrations while overlooking ARA proportionality, spending money without achieving desired supplementation outcomes. High-quality nutritional supplementation hinges not on maximised DHA levels, but on well-balanced, synergistic DHA-to-ARA ratios.

For purchasers, distributors and brand owners, this represents a core product-selection and product-upgrading logic. Many low-end nutritional products on the market contain DHA alone. Though seemingly cost-effective and marketing-friendly, they carry nutritional defects. Consumers often perceive poor efficacy with long-term use, leading to low repurchase rates and unfavourable word-of-mouth. By contrast, products formulated with the DHA+ARA golden ratio (1:1-1:2) align with breast-milk nutritional benchmarks, deliver comprehensive and tangible nutritional benefits, and suit infants across age groups. Such products comply with prevailing market consumption trends, mitigate nutritional-monotonicity-related product weaknesses, and enhance product competitiveness and user reputation.

In summary, DHA+ARA earns its reputation as the "golden duo" in infant nutrition not through simple nutritional addition, but via functional complementarity, metabolic synergy, natural physiological compatibility and amplified health benefits. The greatest limitation of DHA-only supplementation is that it disrupts the body's innate nutritional equilibrium. This not only greatly diminishes brain- and eye-protective effects but may also trigger lags in growth and immune development. Whether parents are supplementing nutrition for children or industry practitioners are selecting and developing products, priority should be given to products with scientifically balanced DHA+ARA ratios, and single-nutrient supplementation should be rejected. Only in this way can efficient, comprehensive nutritional support be realised to safeguard children's healthy development.

References

[1] Yin Shian. Human Milk Composition: Forms, Contents, Functions and Detection Methods [M]. Beijing: Chemical Industry Press, 2016.

[2] Yang Yuexin, Li Ning. Guidelines for the Application of Nutritional Functional Ingredients [M]. Beijing: Peking University Medical Press, 2011.

[3] Chinese Nutrition Society. Chinese Dietary Reference Intakes (2023 Edition) [M]. Beijing: People's Medical Publishing House, 2023.

[4] Hadley K B, Ryan A S, Forsyth S, et al. The essentiality of arachidonic acid in infant development [J]. Nutrients, 2016, 8(4):216.

[5] Birch E E, Garfield S, Hoffman D R, et al. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants [J]. Developmental Medicine and Child Neurology, 2000, 42(3):174-181.

[6] Carlson S E. Docosahexaenoic acid and arachidonic acid in infant development [J]. Seminars in Neonatology, 2001, 6(1):17-29.

[7] Expert Group on DHA Supplementation for Chinese Pregnant, Lactating Women and Infants. Expert consensus on DHA supplementation for Chinese pregnant, lactating women and infants [J]. Chinese Journal of Reproductive Health, 2015, 26(2):101-105.

[8] Koletzko B, et al. Current information and Asian perspectives on long-chain polyunsaturated fatty acids in pregnancy, lactation, and infancy [J]. Annals of Nutrition and Metabolism, 2014, 65:49-80.